IL6R and congenital rubella syndrome: Although there is limited experience with additional therapies, alternate IL-6R antagonists such siltuximab and clazakizumab or the IL-1 receptor antagonist anakinra may be used for CRS refractory to tocilizumab.22–23 Systemic corticosteroids should be added only in refractory, prolonged, or higher-grade CRS.